SCHEMBL148096

SCHEMBL148096

NC(=O)c1cccc2c1[nH]c1cc(NC(=O)C3CCCCN3)ccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 1/20 0.53
JAK2 O60674 3/20 0.47
JAK1 P23458 1/20 0.47
TYK2 P29597 1/20 0.47
JAK3 P52333 1/20 0.47
PSMB8 P28062 2/20 0.46
KHK P50053 1/20 0.41
DHODH Q02127 2/20 0.41
SCN3A Q9NY46 2/20 0.40
SCN9A Q15858 1/20 0.40
PARP1 P09874 3/20 0.40
AAK1 Q2M2I8 1/20 0.40
HDAC2 Q92769 1/20 0.39
SIRT2 Q8IXJ6 1/20 0.39
ALOX15 P16050 1/20 0.38
MAPK1 P28482 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
HSD17B10 Q99714 1/20 0.38
BTK Q06187 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL148095 1.00 ULK1 (0.53) ULK1JAK2JAK1TYK2JAK3
SCHEMBL147871 0.81 AURKA (0.53) ULK1JAK2JAK1TYK2JAK3
SCHEMBL27998034 0.78 JAK2 (0.47) JAK2JAK1TYK2JAK3ALOX15
SCHEMBL146141 0.74 JAK2 (0.51) JAK2JAK1TYK2JAK3BTK
SCHEMBL3697229 0.71 JAK2 (0.59) JAK2JAK1TYK2JAK3PARP1
SCHEMBL149424 0.71 ROCK2 (0.58) JAK2KHKSIRT2
SCHEMBL19233990 0.71 PARP1 (0.55) ULK1PSMB8SCN3ASCN9APARP1
SCHEMBL148108 0.71 AURKA (0.48) JAK2JAK1TYK2JAK3SIRT2
SCHEMBL150480 0.71 JAK2 (0.43) JAK2JAK1TYK2JAK3BTK
SCHEMBL150223 0.70 CHUK (0.49) JAK2PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 ULK1 399/4885JAK2 13/4885JAK1 3/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 ULK1 399/4885JAK2 13/4885JAK1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.